RBC Capital analyst Nik Modi maintains General Mills (NYSE:GIS) with a Sector Perform and raises the price target from $72 to $76.
Melt Pharmaceuticals’ MELT-300, Midazolam 3mg And Ketamine 50mg Sublingual Tablet, Achieves Top-Line Results In Primary Sedation Endpoint In Phase 2 Pivotal Efficacy And Safety Study
MELT-300 Statistically Superior for Procedural Sedation Compared to All Comparator Treatment Arms, Including Midazolam 3mg (P=0.0129) and Ketamine 50mg (P=0.0096)
MELT-300 Treatment Arm 50% Less Likely to Require Rescue Sedation Compared to Midazolam (P=0.0198)
